The road toward AAV-mediated gene therapy of Duchenne muscular dystrophy
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“More recent preclinical developments allow for expression of full-length dystrophins in DMD mouse models (reviewed in Bengtsson et al., 2025), which is achieved by splitting the entire coding sequence over two or three AAVs and using split intein pairs to rejoin the protein products (Tasfaout et al., 2024; Zhou et al., 2024).”
From Understanding Duchenne muscular dystrophy-associated brain pathology (2025) · cites this paper as Bengtsson et al., 2025
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Koenig, M., Hoffman, E. P., Bertelson, C. J., Monaco, A. P., Feener, C., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90504-6 · Cited by 2,411
Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors
Anzalone, A. V., Koblan, L. W., & Liu, D. R. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0561-9 · Cited by 2,237
X chromosome-linked muscular dystrophy (mdx) in the mouse
Bulfield, G., Siller, W. G., Wight, P. A., & Moore, K. J. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.4.1189 · Cited by 1,765
The Molecular Basis of Muscular Dystrophy in the mdx Mouse: a Point Mutation
Sicinski, P., Geng, Y., Ryder-Cook, A. S., Barnard, E. A., Darlison, M. G., & Barnard, P. J. (1989) · Science · doi:10.1126/science.2662404 · Cited by 1,276
Identification of preexisting adaptive immunity to Cas9 proteins in humans
Charlesworth, C. T., Deshpande, P. S., Dever, D. P., Camarena, J., Lemgart, V. T., Cromer, M. K., Vakulskas, C. A., Collingwood, M. A., Zhang, L., Bode, N. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0326-x · Cited by 1,093
In vivo gene editing in dystrophic mouse muscle and muscle stem cells
Tabebordbar, M., Zhu, K., Cheng, J. K. W., Chew, W. L., Widrick, J. J., Yan, W. X., Maesner, C., Wu, E. Y., Xiao, R., Ran, F. A., et al. (2016) · Science · doi:10.1126/science.aad5177 · Cited by 1,046 · cited 2×
“154 For reasons discussed earlier, such RCs are unlikely to be clinically applicable due to unwarranted risks of unintended editing and elicitation of immune responses.”
Richter, M. F., Zhao, K. T., Eton, E., Lapinaite, A., Newby, G. A., Thuronyi, B. W., Wilson, C., Koblan, L. W., Zeng, J., Bauer, D. E., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0453-z · Cited by 1,020
Three muscular dystrophies: loss of cytoskeleton-extracellular matrix linkage
Campbell, K. P. (1995) · Cell · doi:10.1016/0092-8674(95)90344-5 · Cited by 829
Parks, R. J., Chen, L., Anton, M., Sankar, U., Rudnicki, M. A., & Graham, F. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13565 · Cited by 725
Prevention of muscular dystrophy in mice by CRISPR/Cas9–mediated editing of germline DNA
Long, C., McAnally, J. R., Shelton, J. M., Mireault, A. A., Bassel-Duby, R., & Olson, E. N. (2014) · Science · doi:10.1126/science.1254445 · Cited by 720
Dystrophin Immunity in Duchenne's Muscular Dystrophy
Mendell, J. R., Campbell, K., Rodino-Klapac, L., Sahenk, Z., Shilling, C., Lewis, S., Bowles, D., Gray, S., Li, C., Galloway, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000228 · Cited by 655 · cited 1×
“89,90 93 Six different biotech groups have entered the AAV-μ Dys clinical gene therapy space (Figure 1).”
Recombinant adeno-associated virus for muscle directed gene therapy
Fisher, K. J., Jooss, K., Alston, J., Yang, Y., Haecker, S. E., High, K., Pathak, R., Raper, S. E., & Wilson, J. M. (1997) · Nature Medicine · doi:10.1038/nm0397-306 · Cited by 654 · cited 1×
“137,140,141 These observations revealed unique biological properties of AAVs that have expanded the usefulness of this vector system.”
Very mild muscular dystrophy associated with the deletion of 46% of dystrophin
England, S. B., Nicholson, L. V. B., Johnson, M. A., Forrest, S. M., Love, D. R., Zubrzycka-Gaarn, E. E., Bulman, D. E., Harris, J. B., & Davies, K. E. (1990) · Nature · doi:10.1038/343180a0 · Cited by 623 · cited 2×
“14 Unfortunately, gene expression was found to be transient due to cellular immune responses that were elicited by residual, low-level Ad protein expression.”
Systemic delivery of genes to striated muscles using adeno-associated viral vectors
Gregorevic, P., Blankinship, M. J., Allen, J. M., Crawford, R. W., Meuse, L., Miller, D. G., Russell, D. W., & Chamberlain, J. S. (2004) · Nature Medicine · doi:10.1038/nm1085 · Cited by 620 · cited 3×
“82– 84 Muscle-restricted gene expression was important for this approach, as delivery of some bacterial proteins, such as Escherichia coli β -galactosidase ( β -gal) expressed from the ubiquitously active cytomegalovirus (CMV) enhancer/promoter, led to the rapid death of all systemically injected…”
Self-citationAnzalone, A. V., Gao, X. D., Podracky, C. J., Nelson, A. T., Koblan, L. W., Raguram, A., Levy, J. M., Mercer, J. A. M., & Liu, D. R. (2022) · Nature Biotechnology · doi:10.1038/s41587-021-01133-w · Cited by 613
Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy
Amoasii, L., Hildyard, J. C. W., Li, H., Sanchez-Ortiz, E., Mireault, A., Caballero, D., Harron, R., Stathopoulou, T.-R., Massey, C., Shelton, J. M., et al. (2018) · Science · doi:10.1126/science.aau1549 · Cited by 546
Duan, D., Sharma, P., Yang, J., Yue, Y., Dudus, L., Zhang, Y., Fisher, K. J., & Engelhardt, J. F. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8568-8577.1998 · Cited by 522 · cited 1×
“137,140,141 These observations revealed unique biological properties of AAVs that have expanded the usefulness of this vector system.”
Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
Duan, D. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.011 · Cited by 489
Ousterout, D. G., Kabadi, A. M., Thakore, P. I., Majoros, W. H., Reddy, T. E., & Gersbach, C. A. (2015) · Nature Communications · doi:10.1038/ncomms7244 · Cited by 470
High levels of AAV vector integration into CRISPR-induced DNA breaks
Hanlon, K. S., Kleinstiver, B. P., Garcia, S. P., Zaborowski, M. P., Volak, A., Spirig, S. E., Muller, A., Sousa, A. A., Tsai, S. Q., Bengtsson, N. E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12449-2 · Cited by 431 · cited 2×
“165,186 The chief concerns include the integration of AAV vector sequences at sites of CRISPR-induced dsDNA breaks, large genomic rearrangements, and elicited anti-Cas immune responses.”
Self-citationMendell, J. R., Sahenk, Z., Lehman, K., Nease, C., Lowes, L. P., Miller, N. F., Iammarino, M. A., Alfano, L. N., Nicholl, A., Al-Zaidy, S., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1484 · Cited by 405
Phase 1 Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV Vector
Bowles, D. E., McPhee, S. W., Li, C., Gray, S. J., Samulski, J. J., Camp, A. S., Li, J., Wang, B., Monahan, P. E., Rabinowitz, J. E., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.237 · Cited by 400
Bengtsson, N. E., Hall, J. K., Odom, G. L., Phelps, M. P., Andrus, C. R., Hawkins, R. D., Hauschka, S. D., Chamberlain, J. R., & Chamberlain, J. S. (2017) · Nature Communications · doi:10.1038/ncomms14454 · Cited by 387
Self-citationDeath after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne’s Muscular Dystrophy
Lek, A., Wong, B., Keeler, A., Blackwood, M., Ma, K., Huang, S., Sylvia, K., Batista, A. R., Artinian, R., Kokoski, D., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307798 · Cited by 319 · cited 1×
“102 Also, a second Pfizer-treated patient died more than 1 year after treatment, in 2024, although the relationship to the gene therapy treatment remains unclear.”
Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy
Yan, Z., Zhang, Y., Duan, D., & Engelhardt, J. F. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6716 · Cited by 305
Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization
Sun, L., Li, J., & Xiao, X. (2000) · Nature Medicine · doi:10.1038/75087 · Cited by 267
Duan, D., Yue, Y., & Engelhardt, J. F. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0456 · Cited by 262
Weinmann, J., Weis, S., Sippel, J., Tulalamba, W., Remes, A., El Andari, J., Herrmann, A.-K., Pham, Q. H., Borowski, C., Hille, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19230-w · Cited by 259 · cited 1×
“111–113 Such vectors could reduce, if not eliminate, TMA, thrombocytopenia, and liver toxicity.”
Cas9 immunity creates challenges for CRISPR gene editing therapies
Crudele, J. M., & Chamberlain, J. S. (2018) · Nature Communications · doi:10.1038/s41467-018-05843-9 · Cited by 259
Self-citationMendell, J. R., Rodino‐Klapac, L. R., Rosales, X. Q., Coley, B. D., Galloway, G., Lewis, S., Malik, V., Shilling, C., Byrne, B. J., Conlon, T., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22251 · Cited by 248
Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy
Amoasii, L., Long, C., Li, H., Mireault, A. A., Shelton, J. M., Sanchez-Ortiz, E., McAnally, J. R., Bhattacharyya, S., Schmidt, F., Grimm, D., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan8081 · Cited by 247
Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy
Le Guiner, C., Servais, L., Montus, M., Larcher, T., Fraysse, B., Moullec, S., Allais, M., François, V., Dutilleul, M., Malerba, A., et al. (2017) · Nature Communications · doi:10.1038/ncomms16105 · Cited by 246
Salva, M. Z., Himeda, C. L., Tai, P. W., Nishiuchi, E., Gregorevic, P., Allen, J. M., Finn, E. E., Nguyen, Q. G., Blankinship, M. J., Meuse, L., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300027 · Cited by 232 · cited 3×
“…C-terminal domain, 96 while Solid Biosciences uses the most recent μ Dys design, which is the only one that enables localization of nNOS to the DGC. 81 Different MSECs are used in the various trials, although all are muscle specific (Sarepta and Roche, MHCK7 97 ; Genethon and RegenexBio, Spc5.”
Self-citationEfficient in vivo gene expression by trans-splicing adeno-associated viral vectors
Lai, Y., Yue, Y., Liu, M., Ghosh, A., Engelhardt, J. F., Chamberlain, J. S., & Duan, D. (2005) · Nature Biotechnology · doi:10.1038/nbt1153 · Cited by 224 · cited 1×
“125 The study identified two sequences with high splicing activity.”
Self-citationHakim, C. H., Kumar, S. R. P., Pérez-López, D. O., Wasala, N. B., Zhang, D., Yue, Y., Teixeira, J., Pan, X., Zhang, K., Million, E. D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26830-7 · Cited by 175
rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis
Shen, W., Liu, S., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1001263 · Cited by 173
Ghosh, A., Yue, Y., Lai, Y., & Duan, D. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300322 · Cited by 161 · cited 1×
“126,129,147 In these follow-up studies, the Duan lab examined the efficacy of this AAV trans-splicing approach to produce mid-size dystrophin constructs and the therapeutic effects in murine models of DMD via intramuscular injections.”
Koo, T., Popplewell, L., Athanasopoulos, T., & Dickson, G. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.164 · Cited by 104 · cited 1×
“127,131 Two junctions with high consensus splicing value were designed to maximize the splicing activity.”
Gene Therapy of mdx Mice With Large Truncated Dystrophins Generated by Recombination Using rAAV6
Odom, G. L., Gregorevic, P., Allen, J. M., & Chamberlain, J. S. (2011) · Molecular Therapy · doi:10.1038/mt.2010.205 · Cited by 95 · cited 1×
“128 A similar triple AAV approach from this same group to generate full-length dystrophin via homologous recombination resulted in only low levels of the protein (Guy Odom and J.S.C., unpublished observations).”
Self-citationZhang, Y., & Duan, D. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.131 · Cited by 95
Smith, C. J., Ross, N., Kamal, A., Kim, K. Y., Kropf, E., Deschatelets, P., Francois, C., Quinn, W. J., Singh, I., Majowicz, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.999021 · Cited by 86 · cited 1×
“103,105 Together, the ongoing studies of AAV-μ Dys therapy suggest that the current approaches are having a modest impact on patient outcomes, but they also identify several issues that can be addressed to improve efficacy.”
Gonzalez, T. J., Simon, K. E., Blondel, L. O., Fanous, M. M., Roger, A. L., Maysonet, M. S., Devlin, G. W., Smith, T. J., Oh, D. K., Havlik, L. P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33745-4 · Cited by 85
Full-Length Dystrophin Reconstitution with Adeno-Associated Viral Vectors
Lostal, W., Kodippili, K., Yue, Y., & Duan, D. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.210 · Cited by 77
Expression of Human Factor VIII by Splicing between Dimerized AAV Vectors
Chao, H., Sun, L., Bruce, A., Xiao, X., & Walsh, C. E. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0607 · Cited by 75 · cited 1×
“146 For DMD, this method was first tested to express the mini-dystrophin Δ H2-R19, where the authors evaluated the splicing efficiency of four native DMD exon/intron junctions.”
Li, G., Jin, M., Li, Z., Xiao, Q., Lin, J., Yang, D., Liu, Y., Wang, X., Xie, L., Ying, W., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci162809 · Cited by 44 · cited 1×
“200 Intriguingly, miniaturized CRISPR systems may also allow for the incorporation of additional regulatory elements to confer spatiotemporal and drug-inducible control over editing activity.”
Yan, Z., Lei-Butters, D. C. M., Zhang, Y., Zak, R., & Engelhardt, J. F. (2007) · Human Gene Therapy · doi:10.1089/hum.2006.128 · Cited by 41 · cited 1×
“130,131,148 Given the promising data obtained with dual AAV delivery to express various mini-dystrophin constructs, this strategy was evaluated to deliver the full-length dystrophin by administering triple AAV vectors.”
Research works printed but not linked: 154
- Monaco, 1985, Detection of deletions spanning the Duchenne muscular dystrophy locus using a tightly linked DNA segment, Nature, 316, 842, 10.1038/316842a0 · DOI · Paper page
- Monaco, 1986, Isolation of candidate cDNA clones for portions of the Duchenne muscular dystrophy gene, Nature, 323, 646, 10.1038/323646a0 · DOI · Paper page
- Burghes, 1987, A cDNA clone from the Duchenne/Becker muscular dystrophy gene, Nature, 328, 434, 10.1038/328434a0 · DOI · Paper page
- Koenig, 1988, The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein, Cell, 53, 219, 10.1016/0092-8674(88)90383-2 · DOI · Paper page
- Flanigan, 2009, Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort, Hum. Mutat., 30, 1657, 10.1002/humu.21114 · DOI · Paper page
- Monaco, 1988, An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus, Genomics, 2, 90, 10.1016/0888-7543(88)90113-9 · DOI · Paper page
- Malhotra, 1988, Frame-shift deletions in patients with Duchenne and Becker muscular dystrophy, Science, 242, 755, 10.1126/science.3055295 · DOI · Paper page
- Koenig, 1989, The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion, Am. J. Hum. Genet., 45, 498
- Baumbach, 1989, Molecular and clinical correlations of deletions leading to Duchenne and Becker muscular dystrophies, Neurology, 39, 465, 10.1212/WNL.39.4.465 · DOI · Paper page
- Beggs, 1991, Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies, Am. J. Hum. Genet., 49, 54
- Love, 1991, Becker muscular dystrophy patient with a large intragenic dystrophin deletion: Implications for functional minigenes and gene therapy, J. Med. Genet., 28, 860, 10.1136/jmg.28.12.860 · DOI
- Passos-Bueno, 1994, Half the dystrophin gene is apparently enough for a mild clinical course: confirmation of its potential use for gene therapy, Hum. Mol. Genet., 3, 919, 10.1093/hmg/3.6.919 · DOI
- Davies, 2024, Long-term clinical follow-up of a family with Becker muscular dystrophy associated with a large deletion in the DMD gene, Neuromuscul. Disord., 39, 5, 10.1016/j.nmd.2024.04.004 · DOI
- Kunkel, 1986, Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy, Nature, 322, 73, 10.1038/322073a0 · DOI · Paper page
- Chamberlain, 1988, Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification, Nucleic Acids Res., 16, 11141, 10.1093/nar/16.23.11141 · DOI · Paper page
- Beggs, 1990, Detection of 98% of DMD/BMD gene deletions by polymerase chain reaction, Hum. Genet., 86, 45, 10.1007/BF00205170 · DOI · Paper page
- Chamberlain, 1992, Diagnosis of Duchenne and Becker muscular dystrophies by polymerase chain reaction: A multicenter study, JAMA, 267, 2609, 10.1001/jama.1992.03480190051030 · DOI
- Chapman, 1989, Recovery of induced mutations for X chromosome-linked muscular dystrophy in mice, Proc. Natl. Acad. Sci. USA, 86, 1292, 10.1073/pnas.86.4.1292 · DOI · Paper page
- Cox, 1993, New mdx mutation disrupts expression of muscle and nonmuscle isoforms of dystrophin, Nat. Genet., 4, 87, 10.1038/ng0593-87 · DOI · Paper page
- Im, 1996, Differential expression of dystrophin isoforms in strains of mdx mice with different mutations, Hum. Mol. Genet., 5, 1149, 10.1093/hmg/5.8.1149 · DOI · Paper page
- Zubrzycka-Gaarn, 1988, The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle, Nature, 333, 466, 10.1038/333466a0 · DOI · Paper page
- Hoffman, 1987, Dystrophin: the protein product of the Duchenne muscular dystrophy locus, Cell, 51, 919, 10.1016/0092-8674(87)90579-4 · DOI · Paper page
- Hoffman, 1988, Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy, N. Engl. J. Med., 318, 1363, 10.1056/NEJM198805263182104 · DOI · Paper page
- Ervasti, 1991, Membrane organization of the dystrophin-glycoprotein complex, Cell, 66, 1121, 10.1016/0092-8674(91)90035-W · DOI · Paper page
- Ibraghimov-Beskrovnaya, 1992, Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix, Nature, 355, 696, 10.1038/355696a0 · DOI · Paper page
- Wan, 2025, Structure and assembly of the dystrophin glycoprotein complex, Nature, 637, 1252, 10.1038/s41586-024-08310-2 · DOI
- Liu, 2025, Native DGC structure rationalizes muscular dystrophy-causing mutations, Nature, 637, 1261, 10.1038/s41586-024-08324-w · DOI
- Brenman, 1995, Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy, Cell, 82, 743, 10.1016/0092-8674(95)90471-9 · DOI · Paper page
- Montanaro, 1999, alpha-Dystroglycan is a laminin receptor involved in extracellular matrix assembly on myotubes and muscle cell viability, J. Cell Biol., 145, 1325, 10.1083/jcb.145.6.1325 · DOI
- Ramaswamy, 2011, Lateral transmission of force is impaired in skeletal muscles of dystrophic mice and very old rats, J. Physiol., 589, 1195, 10.1113/jphysiol.2010.201921 · DOI · Paper page
- Lee, 1991, Expression of recombinant dystrophin and its localization to the cell membrane, Nature, 349, 334, 10.1038/349334a0 · DOI
- Jaynes, 1988, The muscle creatine kinase gene is regulated by multiple upstream elements, including a muscle-specific enhancer, Mol. Cell. Biol., 8, 62
- Cox, 1993, Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity [see comments], Nature, 364, 725, 10.1038/364725a0 · DOI · Paper page
- Scott, 2002, Viral vectors for gene transfer of micro-mini-or full-length dystrophin, Neuromuscul. Disord., 12, S23, 10.1016/S0960-8966(02)00078-0 · DOI
- Wolff, 1990, Direct gene transfer into mouse muscle in vivo, Science, 247, 1465, 10.1126/science.1690918 · DOI · Paper page
- Fritz, 1995, Expression of deletion-containing dystrophins in mdx muscle: implications for gene therapy and dystrophin function, Pediatr. Res., 37, 693, 10.1203/00006450-199506000-00004 · doi:10.1203/00006450-199506000-00004
- Acsadi, 1991, Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs, Nature, 352, 815, 10.1038/352815a0 · DOI · Paper page
- Romero, 2004, Phase I Study of Dystrophin Plasmid-Based Gene Therapy in Duchenne/Becker Muscular Dystrophy, Hum. Gene Ther., 15, 1065, 10.1089/hum.2004.15.1065 · DOI
- Stratford-Perricaudet, 1992, Widespread long-term gene transfer to mouse skeletal muscles and heart, J. Clin. Invest., 90, 626, 10.1172/JCI115902 · DOI · Paper page
- Ragot, 1993, Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice, Nature, 361, 647, 10.1038/361647a0 · DOI · Paper page
- Acsadi, 1994, A differential efficiency of adenovirus-mediated in vivo gene transfer into skeletal muscle cells of different maturity, Hum. Mol. Genet., 3, 579, 10.1093/hmg/3.4.579 · DOI · Paper page
- Zoltick, 2001, Biology of E1-deleted adenovirus vectors in nonhuman primate muscle, J. Virol., 75, 5222, 10.1128/JVI.75.11.5222-5229.2001 · DOI
- Carmen, 2001, A death in the laboratory: the politics of the Gelsinger aftermath, Mol. Ther., 3, 425, 10.1006/mthe.2001.0305 · DOI
- Mitani, 1995, Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector, Proc. Natl. Acad. Sci. USA, 92, 3854, 10.1073/pnas.92.9.3854 · DOI · Paper page
- Kumar-Singh, 1996, Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells, Hum. Mol. Genet., 5, 913, 10.1093/hmg/5.7.913 · DOI · Paper page
- Greelish, 1999, Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector, Nat. Med., 5, 439, 10.1038/7439 · DOI · Paper page
- DelloRusso, 2002, Functional correction of adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin, Proc. Natl. Acad. Sci. USA, 99, 12979, 10.1073/pnas.202300099 · DOI · Paper page
- Dunckley, 1993, Direct retroviral-mediated transfer of a dystrophin minigene into mdx mouse muscle in vivo, Hum. Mol. Genet., 2, 717, 10.1093/hmg/2.6.717 · DOI
- Roberts, 2002, Stable micro-dystrophin gene transfer using an integrating adeno-retroviral hybrid vector ameliorates the dystrophic pathology in mdx mouse muscle, Hum. Mol. Genet., 11, 1719, 10.1093/hmg/11.15.1719 · DOI
- Kobinger, 2003, Correction of the dystrophic phenotype by in vivo targeting of muscle progenitor cells, Hum. Gene Ther., 14, 1441, 10.1089/104303403769211655 · DOI
- Kimura, 2010, Dystrophin delivery to muscles of mdx mice using lentiviral vectors leads to myogenic progenitor targeting and stable gene expression, Mol. Ther., 18, 206, 10.1038/mt.2009.253 · DOI · Paper page
- Hindi, 2023, Enveloped viruses pseudotyped with mammalian myogenic cell fusogens target skeletal muscle for gene delivery, Cell, 186, 2062, 10.1016/j.cell.2023.03.033 · DOI
- Kessler, 1996, Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein, Proc. Natl. Acad. Sci. USA, 93, 14082, 10.1073/pnas.93.24.14082 · DOI · Paper page
- Xiao, 1996, Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector, J. Virol., 70, 8098, 10.1128/jvi.70.11.8098-8108.1996 · DOI · Paper page
- Muzyczka, 1992, Use of adeno-associated virus as a general transduction vector for mammalian cells, Curr. Top. Microbiol. Immunol., 158, 97
- Corrado, 1996, Transgenic mdx mice expressing dystrophin with a deletion in the actin-binding domain display a “mild Becker” phenotype, J. Cell Biol., 134, 873, 10.1083/jcb.134.4.873 · DOI · Paper page
- Warner, 2002, Expression of Dp260 in muscle tethers the actin cytoskeleton to the dystrophin-glycoprotein complex and partially prevents dystrophy, Hum. Mol. Genet., 11, 1095, 10.1093/hmg/11.9.1095 · DOI
- Phelps, 1995, Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice, Hum. Mol. Genet., 4, 1251, 10.1093/hmg/4.8.1251 · DOI · Paper page
- Wells, 1995, Expression of human full-length and minidystrophin in transgenic mdx mice: implications for gene therapy of Duchenne muscular dystrophy, Hum. Mol. Genet., 4, 1245, 10.1093/hmg/4.8.1245 · DOI · Paper page
- Harper, 2002, Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy, Nat. Med., 8, 253, 10.1038/nm0302-253 · DOI · Paper page
- Harper, 2002, Spectrin-like repeats from dystrophin and alpha-actinin-2 are not functionally interchangeable, Hum. Mol. Genet., 11, 1807, 10.1093/hmg/11.16.1807 · DOI
- Rafael, 1994, Prevention of dystrophic pathology in mdx mice by a truncated dystrophin isoform, Hum. Mol. Genet., 3, 1725, 10.1093/hmg/3.10.1725 · DOI
- Crawford, 2000, Assembly of the dystrophin-associated protein complex does not require the dystrophin COOH-terminal domain, J. Cell Biol., 150, 1399, 10.1083/jcb.150.6.1399 · DOI · Paper page
- Rafael, 1996, Forced expression of dystrophin deletion constructs reveals structure-function correlations, J. Cell Biol., 134, 93, 10.1083/jcb.134.1.93 · DOI · Paper page
- Jaynes, 1986, Transcriptional regulation of the muscle creatine kinase gene and regulated expression in transfected mouse myoblasts, Mol. Cell. Biol., 6, 2855
- Wang, 2000, Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model, Proc. Natl. Acad. Sci. USA, 97, 13714, 10.1073/pnas.240335297 · DOI · Paper page
- Sakamoto, 2002, Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene, Biochem. Biophys. Res. Commun., 293, 1265, 10.1016/S0006-291X(02)00362-5 · DOI
- Bostick, 2008, Adeno-Associated Virus Serotype-9 Microdystrophin Gene Therapy Ameliorates Electrocardiographic Abnormalities in mdx Mice, Hum. Gene Ther., 19, 851, 10.1089/hum.2008.058 · DOI · Paper page
- Lai, 2009, Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy, J. Clin. Invest., 119, 624, 10.1172/JCI36612 · DOI · Paper page
- Banks, 2007, Functional capacity of dystrophins carrying deletions in the N-terminal actin-binding domain, Hum. Mol. Genet., 16, 2105, 10.1093/hmg/ddm158 · DOI · Paper page
- Banks, 2010, The polyproline site in hinge 2 influences the functional capacity of truncated dystrophins, PLoS Genet., 6, 10.1371/journal.pgen.1000958 · DOI · Paper page
- Ramos, 2019, Development of novel micro-dystrophins with enhanced functionality, Mol. Ther., 27, 623, 10.1016/j.ymthe.2019.01.002 · DOI · Paper page
- Hauser, 2000, Analysis of muscle creatine kinase regulatory elements in recombinant adenoviral vectors, Mol. Ther., 2, 16, 10.1006/mthe.2000.0089 · DOI · Paper page
- Gregorevic, 2006, rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice, Nat. Med., 12, 787, 10.1038/nm1439 · DOI · Paper page
- Hartigan-O'Connor, 2001, Immune evasion by muscle-specific gene expression in dystrophic muscle, Mol. Ther., 4, 525, 10.1006/mthe.2001.0496 · DOI · Paper page
- Stedman, 2000, Phase I clinical trial utilizing gene therapy for limb girdle muscular dystrophy: alpha-beta-gamma-or delta-sarcoglycan gene delivered with intramuscular instillations of adeno-associated vectors, Hum. Gene Ther., 11, 777, 10.1089/10430340050015671 · DOI
- Mendell, 2009, Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins, Ann. Neurol., 66, 290, 10.1002/ana.21732 · DOI · Paper page
- Mendell, 2024, Practical Considerations for Delandistrogene Moxeparvovec Gene Therapy in Patients With Duchenne Muscular Dystrophy, Pediatr. Neurol., 153, 11, 10.1016/j.pediatrneurol.2024.01.003 · DOI
- Morris, 2022, IGNITE DMD Study of SGT-001 Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy: Long-Term Outcomes and Biomarker Update, Mol. Ther., 30, 553
- Crudele, 2019, AAV-based gene therapies for the muscular dystrophies, Hum. Mol. Genet., 28, R102, 10.1093/hmg/ddz128 · DOI · Paper page
- Koo, 2011, Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-terminal domain of dystrophin improves muscle pathology and restores the level of alpha1-syntrophin and alpha-dystrobrevin in skeletal muscles of mdx mice, Hum. Gene Ther., 22, 1379, 10.1089/hum.2011.020 · DOI · Paper page
- Li, 1999, Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences, Nat. Biotechnol., 17, 241, 10.1038/6981 · DOI · Paper page
- Towbin, 1993, X-linked dilated cardiomyopathy: Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus, Circulation, 87, 1854, 10.1161/01.CIR.87.6.1854 · DOI · Paper page
- Townsend, 2009, Cardiac consequences to skeletal muscle-centric therapeutics for Duchenne muscular dystrophy, Trends Cardiovasc. Med., 19, 50, 10.1016/j.tcm.2009.04.006 · DOI
- Townsend, 2008, Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle, Mol. Ther., 16, 832, 10.1038/mt.2008.52 · DOI · Paper page
- Servais, 2023, 261st ENMC International Workshop: Management of safety issues arising following AAV gene therapy. 17th-19th June 2022, Hoofddorp, The Netherlands, Neuromuscul. Disord., 33, 884, 10.1016/j.nmd.2023.09.008 · DOI
- Bonnemann, 2023, Dystrophin Immunity after Gene Therapy for Duchenne's Muscular Dystrophy, N. Engl. J. Med., 388, 2294, 10.1056/NEJMc2212912 · DOI
- Yue, 2008, A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs, Mol. Ther., 16, 1944, 10.1038/mt.2008.207 · DOI · Paper page
- Le Guiner, 2023, Evaluation of an AAV9-mini-dystrophin gene therapy candidate in a rat model of Duchenne muscular dystrophy, Mol. Ther. Methods Clin. Dev., 30, 30, 10.1016/j.omtm.2023.05.017 · DOI
- Birch, 2023, Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy, Sci. Transl. Med., 15, 10.1126/scitranslmed.abo1815 · DOI
- Tasfaout, 2024, Split intein-mediated protein trans-splicing to express large dystrophins, Nature, 632, 192, 10.1038/s41586-024-07710-8 · DOI · Paper page
- Tabebordbar, 2021, Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species, Cell, 184, 4919, 10.1016/j.cell.2021.08.028 · DOI · Paper page
- Odom, 2008, Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice, Mol. Ther., 16, 1539, 10.1038/mt.2008.149 · DOI · Paper page
- Kennedy, 2018, Micro-utrophin Improves Cardiac and Skeletal Muscle Function of Severely Affected D2/mdx Mice, Mol. Ther. Methods Clin. Dev., 11, 92, 10.1016/j.omtm.2018.10.005 · DOI
- Song, 2019, Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models, Nat. Med., 25, 1505, 10.1038/s41591-019-0594-0 · DOI · Paper page
- Odom, 2022, Deimmunized micro-dystrophin vectors blunt patient immunity in vitro & restore cardiac functional deficits in vivo in mdx4cv DMD mice, Mol. Ther., 30, 20
- Liu, 2022, Obtaining protein foldability information from computational models of AlphaFold2 and RoseTTAFold, Comput. Struct. Biotechnol. J., 20, 4481, 10.1016/j.csbj.2022.08.034 · DOI
- Schoeder, 2021, Modeling Immunity with Rosetta: Methods for Antibody and Antigen Design, Biochemistry, 60, 825, 10.1021/acs.biochem.0c00912 · DOI
- Rohl, 2004, Protein structure prediction using Rosetta, Methods Enzymol., 383, 66, 10.1016/S0076-6879(04)83004-0 · DOI · Paper page
- Wasala, 2018, Cardiac-Specific Expression of DeltaH2-R15 Mini-Dystrophin Normalized All Electrocardiogram Abnormalities and the End-Diastolic Volume in a 23-Month-Old Mouse Model of Duchenne Dilated Cardiomyopathy, Hum. Gene Ther., 29, 737, 10.1089/hum.2017.144 · DOI
- El Andari, 2022, Semirational bioengineering of AAV vectors with increased potency and specificity for systemic gene therapy of muscle disorders, Sci. Adv., 8, 10.1126/sciadv.abn4704 · DOI
- Vu Hong, 2024, An engineered AAV targeting integrin alpha V beta 6 presents improved myotropism across species, Nat. Commun., 15, 7965, 10.1038/s41467-024-52002-4 · DOI
- Kodippili, 2018, Dual AAV Gene Therapy for Duchenne Muscular Dystrophy with a 7-kb Mini-Dystrophin Gene in the Canine Model, Hum. Gene Ther., 29, 299, 10.1089/hum.2017.095 · DOI · Paper page
- Albini, 2023, Assessment of Therapeutic Potential of a Dual AAV Approach for Duchenne Muscular Dystrophy, Int. J. Mol. Sci., 24, 10.3390/ijms241411421 · DOI
- Lindley, 2024, Ribozyme-activated mRNA trans-ligation enables large gene delivery to treat muscular dystrophies, Science, 386, 762, 10.1126/science.adp8179 · DOI
- Li, 2008, Protein trans-splicing as a means for viral vector-mediated in vivo gene therapy, Hum. Gene Ther., 19, 958, 10.1089/hum.2008.009 · DOI · Paper page
- Tasfaout, 2025, Expression of full-length dystrophin reverses muscular dystrophy defects in young and old mdx4cv mice., manuscript in revision
- Zhou, 2024, Systemic delivery of full-length dystrophin in Duchenne muscular dystrophy mice, Nat. Commun., 15
- Palmieri, 2024, In Silico Structural Prediction for the Generation of Novel Performant Midi-Dystrophins Based on Intein-Mediated Dual AAV Approach, Int. J. Mol. Sci., 25, 10.3390/ijms251910444 · DOI
- Herzog, 1997, Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus, Proc. Natl. Acad. Sci. USA, 94, 5804, 10.1073/pnas.94.11.5804 · DOI · Paper page
- Kaplitt, 1994, Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain, Nat. Genet., 8, 148, 10.1038/ng1094-148 · DOI · Paper page
- Yang, 1999, Concatamerization of adeno-associated virus circular genomes occurs through intermolecular recombination, J. Virol., 73, 9468, 10.1128/JVI.73.11.9468-9477.1999 · DOI · Paper page
- Nakai, 2000, Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors, Nat. Biotechnol., 18, 527, 10.1038/75390 · DOI · Paper page
- Li, 2015, Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9, Stem Cel. Rep., 4, 143, 10.1016/j.stemcr.2014.10.013 · DOI · Paper page
- Long, 2016, Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy, Science, 351, 400, 10.1126/science.aad5725 · DOI · Paper page
- Nelson, 2016, In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy, Science, 351, 403, 10.1126/science.aad5143 · DOI · Paper page
- Bengtsson, 2016, Progress and prospects of gene therapy clinical trials for the muscular dystrophies, Hum. Mol. Genet., 25, R9, 10.1093/hmg/ddv420 · DOI · Paper page
- Xu, 2016, CRISPR-mediated Genome Editing Restores Dystrophin Expression and Function in mdx Mice, Mol. Ther., 24, 564, 10.1038/mt.2015.192 · DOI · Paper page
- Moretti, 2020, Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy, Nat. Med., 26, 207, 10.1038/s41591-019-0738-2 · DOI · Paper page
- Bengtsson, 2022, Comparison of dystrophin expression following gene editing and gene replacement in an aged preclinical DMD animal model, Mol. Ther., 30, 2176, 10.1016/j.ymthe.2022.02.003 · DOI
- Nelson, 2019, Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy, Nat. Med., 25, 427, 10.1038/s41591-019-0344-3 · DOI · Paper page
- Bengtsson, 2021, Dystrophin gene-editing stability is dependent on dystrophin levels in skeletal but not cardiac muscles, Mol. Ther., 29, 1070, 10.1016/j.ymthe.2020.11.003 · DOI
- Mauro, 1961, Satellite cell of skeletal muscle fibers, J. Biophys. Biochem. Cytol., 9, 493, 10.1083/jcb.9.2.493 · DOI · Paper page
- Goldstein, 2019, In situ modification of tissue stem and progenitor cell genomes, Cell Rep., 27, 1254, 10.1016/j.celrep.2019.03.105 · DOI
- Kwon, 2020, In vivo gene editing of muscle stem cells with adeno-associated viral vectors in a mouse model of Duchenne muscular dystrophy, Mol. Ther. Methods Clin. Dev., 19, 320, 10.1016/j.omtm.2020.09.016 · DOI
- Nance, 2019, AAV9 edits muscle stem cells in normal and dystrophic adult mice, Mol. Ther., 27, 1568, 10.1016/j.ymthe.2019.06.012 · DOI
- Young, 2016, A single crispr-cas9 deletion strategy that targets the majority of DMD patients restores dystrophin function in hIPSC-derived muscle cells, Cell Stem Cell, 18, 533, 10.1016/j.stem.2016.01.021 · DOI · Paper page
- Goyenvalle, 2004, Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping, Science, 306, 1796, 10.1126/science.1104297 · DOI · Paper page
- Vulin, 2012, Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping, Mol. Ther., 20, 2120, 10.1038/mt.2012.181 · DOI
- Aupy, 2020, Long-Term Efficacy of AAV9-U7snRNA-Mediated Exon 51 Skipping in mdx52 Mice, Mol. Ther. Methods Clin. Dev., 17, 1037, 10.1016/j.omtm.2020.04.025 · DOI · Paper page
- Wein, 2022, Systemic delivery of an AAV9 exon-skipping vector significantly improves or prevents features of Duchenne muscular dystrophy in the Dup2 mouse, Mol. Ther. Methods Clin. Dev., 26, 279, 10.1016/j.omtm.2022.07.005 · DOI
- Gushchina, 2023, Persistence of exon 2 skipping and dystrophin expression at 18 months after U7snRNA-mediated therapy in the Dup2 mouse model, Mol. Ther. Methods Clin. Dev., 31, 10.1016/j.omtm.2023.101144 · DOI
- Maino, 2021, Targeted genome editing in vivo corrects a Dmd duplication restoring wild-type dystrophin expression, EMBO Mol. Med., 13, 10.15252/emmm.202013228 · DOI
- Gushchina, 2021, Lack of Toxicity in Nonhuman Primates Receiving Clinically Relevant Doses of an AAV9.U7snRNA Vector Designed to Induce DMD Exon 2 Skipping, Hum. Gene Ther., 32, 882, 10.1089/hum.2020.286 · DOI
- Anzalone, 2019, Search-and-replace genome editing without double-strand breaks or donor DNA, Nature, 576, 149, 10.1038/s41586-019-1711-4 · DOI · Paper page
- Chemello, 2021, Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing, Sci. Adv., 7, 10.1126/sciadv.abg4910 · DOI · Paper page
- Xu, 2021, Efficient precise in vivo base editing in adult dystrophic mice, Nat. Commun., 12, 3719, 10.1038/s41467-021-23996-y · DOI · Paper page
- Lin, 2024, Adenine base editing-mediated exon skipping restores dystrophin in humanized Duchenne mouse model, Nat. Commun., 15, 5927, 10.1038/s41467-024-50340-x · DOI
- Duchene, 2018, CRISPR-induced deletion with saCas9 restores dystrophin expression in dystrophic models in vitro and in vivo, Mol. Ther., 26, 2604, 10.1016/j.ymthe.2018.08.010 · DOI
- Choi, 2022, Precise genomic deletions using paired prime editing, Nat. Biotechnol., 40, 218, 10.1038/s41587-021-01025-z · DOI · Paper page
- Happi Mbakam, 2022, Prime editing permits the introduction of specific mutations in the gene responsible for Duchenne muscular dystrophy, Int. J. Mol. Sci., 23, 10.3390/ijms23116160 · DOI
- Pickar-Oliver, 2021, Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy, Mol. Ther., 29, 3243, 10.1016/j.ymthe.2021.09.003 · DOI
- Tasca, 2022, Large-scale genome editing based on high-capacity adenovectors and CRISPR-Cas9 nucleases rescues full-length dystrophin synthesis in DMD muscle cells, Nucleic Acids Res., 50, 7761, 10.1093/nar/gkac567 · DOI
- Stephenson, 2023, CRISPR-Cas9 homology-independent targeted integration of exons 1-19 restores full-length dystrophin in mice, Mol. Ther. Methods Clin. Dev., 30, 486, 10.1016/j.omtm.2023.08.009 · DOI
- Pandey, 2025, Efficient site-specific integration of large genes in mammalian cells via continuously evolved recombinases and prime editing, Nat. Biomed. Eng., 9, 22, 10.1038/s41551-024-01227-1 · DOI · Paper page
- Kenjo, 2021, Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice, Nat. Commun., 12, 7101, 10.1038/s41467-021-26714-w · DOI · Paper page
- Wei, 2020, Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing, Nat. Commun., 11, 3232, 10.1038/s41467-020-17029-3 · DOI · Paper page
- Harrington, 2018, Programmed DNA destruction by miniature CRISPR-Cas14 enzymes, Science, 362, 839, 10.1126/science.aav4294 · DOI · Paper page
- Pausch, 2020, CRISPR-CasPhi from huge phages is a hypercompact genome editor, Science, 369, 333, 10.1126/science.abb1400 · DOI · Paper page
- Xu, 2021, Engineered miniature CRISPR-Cas system for mammalian genome regulation and editing, Mol. Cell, 81, 4333, 10.1016/j.molcel.2021.08.008 · DOI · Paper page
- Kong, 2023, Engineered CRISPR-OsCas12f1 and RhCas12f1 with robust activities and expanded target range for genome editing, Nat. Commun., 14, 2046, 10.1038/s41467-023-37829-7 · DOI
- Monteys, 2021, Regulated control of gene therapies by drug-induced splicing, Nature, 596, 291, 10.1038/s41586-021-03770-2 · DOI
- Arnett, 2014, Adeno-associated viral vectors do not efficiently target muscle satellite cells, Mol. Ther. Methods Clin. Dev., 1, 10.1038/mtm.2014.38 · DOI · Paper page
- Hauschka, 2024, Targeting muscle stem cells for permanent correction of dystrophin expression in Duchenne muscular dystrophy, Mol. Ther., 32, 550
Cited by
Understanding Duchenne muscular dystrophy-associated brain pathology
Verhaeg, M. A. T., Govaarts, R., & van Putten, M. (2025) · Disease Models & Mechanisms · doi:10.1242/dmm.052302 · Cited by 5
Metadata
- Authors
- Bengtsson, N. E., Tasfaout, H., & Chamberlain, J. S.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2025-05
- Volume
- 33
- Issue
- 5
- Pages
- 2035-2051
- ISSN
- 1525-0016
- Cited by
- 40
- References
- 46
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- US Department of Defense (MD220097)
- Muscular Dystrophy Association
- Philippe Foundation
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (P50AR065139, R01AR040864)
- National Institutes of Health
- Association Française contre les Myopathies
- AFM-Téléthon
- Defeat Duchenne Canada
- Fondation Bettencourt Schueller
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.